Compounds > 2-acetamido-n-benzyl-2-methylacetamide
Page last updated: 2024-11-07

2-acetamido-n-benzyl-2-methylacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-acetamido-N-benzyl-2-methylacetamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135813
CHEMBL ID56378
SCHEMBL ID993570
MeSH IDM0191894

Synonyms (17)

Synonym
2-abma
AKOS001401474
CHEMBL56378
2-acetamido-n-benzyl-2-methylacetamide
86921-48-4
2-acetamido-n-benzylpropanamide
93782-09-3
AKOS016862006
SCHEMBL993570
n-benzyl-2-acetamidopropanamide
n-benzyl-2-acetamidopropionamide
DTXSID701007185
n-benzyl-2-[(1-hydroxyethylidene)amino]propanimidic acid
CS-0276846
2-(acetylamino)-n-(phenylmethyl)propanamide
STARBLD0029161
Z27749349
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID115771Anticonvulsant against maximal electroshock induced convulsions after 30 min.1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID136259Neurological toxicity was determined using horizontal screen test in mice after intraperitoneal administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.
AID113972Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase III Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID113975Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions (sc MET)(Phase IV Pharmacological Evaluation); No toxicity observed up to 100 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID687774Neurotoxicity in ip dosed NMRI mouse assessed as minimal motor impairment after 30 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.
AID226942Protectivity index is the ratio of TD50 /MES ED50 from Phase-II evaluation1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID122028Toxic dose was evaluated by neurological toxicity (the rotarod test)1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID121863Neurologic toxicity activity was determined by rotarod toxicity test (Phase II Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID113984Anticonvulsant activity was determined by subcutaneous pentylenetetrazole seizure test (Phase IV Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID189456Protective index between TD50/MES ED50 when administered orally to rat1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.
AID226943Protectivity index is the ratio of TD50 /MES ED50 from Phase-IV evaluation1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID109510Anticonvulsant activity was evaluated by Neurologic toxicity (the rotarod test) at dose 600 mg/kg; 1=Noticeable activity1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID113858Effective dose against maximal electroshock seizure in mice after intraperitoneal administration1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.
AID115916Anticonvulsant against s.c. Metrazol-induced convulsions after 30 min.1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID117856Protective index between TD50/MES ED50 when administered intraperitoneally to mice1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.
AID29307Neurotoxic dose (TD50) in mice using the rotarod test1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.
AID113971Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase II Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID687765Anticonvulsant activity in ip dosed CF1 mouse assessed as protection against maximal electroshock-induced seizure after 30 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.
AID131201Concentration required to inhibit seizures was determined in MES test after (ip) administration in mice1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.
AID687767Anticonvulsant activity in ip dosed CF1 mouse assessed as time of peak effect for protection against maximal electroshock-induced seizure2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.
AID113153Concentration required to prevent seizures upon intraperitoneal administration in mice in MES (maximal electroshock seizure) test.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.
AID113982Anticonvulsant activity was determined by subcutaneous bicuculline test (CD97=2.70 mg/kg) (Phase V Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID109524Anticonvulsant activity was evaluated by subcutaneous pentylenetetrazole (Metrazol) (sc Met) seizure test at dose 600 mg/kg; No activity1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID122000Neurotoxic toxicity was evaluated by rotarod test after intraperitoneal administration1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.
AID112170Effective dose was evaluated by maximal electroshock seizure (MES) test1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID113012In vivo anticonvulsant activity in male albino mice using the maximal electroshock seizure(MES) test upon intraperitoneal administration; value ranges from 66.5 to 892002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Quantitative structure-activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods.
AID687775Neurotoxicity in ip dosed NMRI mouse assessed as time of peak effect for minimal motor impairment after 30 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.
AID124465Anticonvulsant activity was determined by rotarod toxicity test (neurologic toxicity) at an interval of 0.5 h1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID113985Anticonvulsant activity was determined by subcutaneous picrotoxin test (CD97=3.15 mg/kg) (Phase V Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID109514Anticonvulsant activity was evaluated by maximal electroshock seizure (MES) test at dose 100 mg/kg; 3=Noticeable activity1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID178377Effective dose against maximal electroshock seizure in rat after oral administration1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.
AID124082In vivo anticonvulsant activity in male albino mice using the maximal electroshock seizure(MES) test upon intraperitoneal administration, expressed as logarithm of effective dose2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Quantitative structure-activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's3 (42.86)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.40 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
5-phenylhydantoin, (+-)-isomer
5-phenylhydantoin: structure given in first source		1.9610
phenytoin
[no description available]		3.2360imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		3.0850branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
ethosuximide
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.		1.9710dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		1.9610imidazolidine-2,4-dioneanticonvulsant
phenacemide
phenacemide: anti-epileptic drug; structure		1.9610acetamides
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		3.0850barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
5-methylhydantoin
5-methylhydantoin: RN given refers to cpd without isomeric designation		1.9610imidazolidine-2,4-dione
alpha-acetamido-n-benzyl-alpha-(furan-2-yl)acetamide
alpha-acetamido-N-benzyl-alpha-(furan-2-yl)acetamide: RN given refers to (+-)-isomer; structure given in first source		2.6830
lacosamide
Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.		2.4220N-acyl-amino acid
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		1.9710chalcogen;
nonmetal atom		macronutrient
lacosamide
[no description available]		2.7130
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		02.6830
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.6830
Aura
[description not available]		01.9710
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		01.9710
Nerve Pain
[description not available]		02.0610
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.0610